Overview

Etoricoxib Versus Gabapentin for Knee Arthroscopy

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
To determine that when administered as part of a multimodal analgesic regimen, use of the new COX-2 antagonist etoricoxib (120 mg/day, per os) is more effective in improving postoperative pain management after knee arthroscopy than gabapentin (1.2 g/day, per os).
Phase:
Phase 4
Details
Lead Sponsor:
Meir Medical Center
Treatments:
Etoricoxib
Gabapentin
gamma-Aminobutyric Acid